KR20190094222A - 다가 조절성 t 세포 조절제 - Google Patents

다가 조절성 t 세포 조절제 Download PDF

Info

Publication number
KR20190094222A
KR20190094222A KR1020197020221A KR20197020221A KR20190094222A KR 20190094222 A KR20190094222 A KR 20190094222A KR 1020197020221 A KR1020197020221 A KR 1020197020221A KR 20197020221 A KR20197020221 A KR 20197020221A KR 20190094222 A KR20190094222 A KR 20190094222A
Authority
KR
South Korea
Prior art keywords
ser
leu
val
lys
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197020221A
Other languages
English (en)
Korean (ko)
Inventor
제프리 그리브
정민 김
니란자나 나가라잔
존 조
Original Assignee
데리니아, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 데리니아, 인크. filed Critical 데리니아, 인크.
Publication of KR20190094222A publication Critical patent/KR20190094222A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
KR1020197020221A 2016-12-13 2017-12-13 다가 조절성 t 세포 조절제 Ceased KR20190094222A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662433533P 2016-12-13 2016-12-13
US62/433,533 2016-12-13
PCT/US2017/066163 WO2018112069A1 (en) 2016-12-13 2017-12-13 Multivalent regulatory t cell modulators

Publications (1)

Publication Number Publication Date
KR20190094222A true KR20190094222A (ko) 2019-08-12

Family

ID=62488540

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197020221A Ceased KR20190094222A (ko) 2016-12-13 2017-12-13 다가 조절성 t 세포 조절제

Country Status (11)

Country Link
US (2) US10472405B2 (https=)
EP (1) EP3554525A4 (https=)
JP (1) JP7228515B2 (https=)
KR (1) KR20190094222A (https=)
CN (1) CN110177564A (https=)
AU (1) AU2017378308A1 (https=)
BR (2) BR112019011799B1 (https=)
CA (1) CA3044416A1 (https=)
MX (2) MX381276B (https=)
RU (1) RU2769871C2 (https=)
WO (1) WO2018112069A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840545B2 (en) 2013-09-20 2017-12-12 University Of Virginia Patent Foundation Fusion protein comprising interleukin-2 and interleukin-33
AU2017378308A1 (en) 2016-12-13 2019-06-20 Delinia, Inc. Multivalent regulatory T cell modulators
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
BR112021002250A2 (pt) 2018-08-06 2021-07-20 Medikine, Inc. compostos de ligação ao receptor de il-2
AU2019369498A1 (en) * 2018-10-31 2021-05-20 Delinia, Inc. Multivalent regulatory T cell modulators
BR112021023345A2 (pt) 2019-05-20 2022-02-01 Pandion Operations Inc Imunotolerância com alvo em madcam
JP2022536581A (ja) * 2019-06-19 2022-08-18 キュー バイオファーマ， インコーポレイテッド 多量体ｔ細胞調節性ポリペプチド及びその使用方法
CN114853874B (zh) * 2019-09-10 2024-05-17 中国医学科学院北京协和医院 靶向调节t细胞的长效白介素-2及其在治疗自身免疫病中的应用
IL292803A (en) 2019-11-05 2022-07-01 Medikine Inc Dual il-2 receptor and il-7 receptor binding compounds, compositions comprising same and uses thereof
JP7427286B2 (ja) 2019-11-05 2024-02-05 メディカイン、インコーポレイテッド ＩＬ－２ＲβγＣ結合化合物
MX2022009302A (es) 2020-02-03 2022-11-16 Medikine Inc Compuestos de unión a il-7r¿.
CA3166816A1 (en) 2020-02-03 2021-08-12 William J. Dower Il-7r.alpha..gamma.c binding compounds
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
US11999771B2 (en) 2022-04-07 2024-06-04 Medikine, Inc. IL-7Rαγc ligand immunoglobulin fusion proteins
CA3247209A1 (en) * 2022-05-11 2023-11-16 Slate Bio, Inc. COMPOSITIONS COMPRISING INTERLEUKIN-2 AND TRUNCATED INTERLEUKIN-33
WO2025106677A1 (en) * 2023-11-15 2025-05-22 Slate Bio, Inc. Bifunctional il-2 and il-33 proteins for treating autoimmune disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DZ2788A1 (fr) * 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US7754855B1 (en) * 1999-07-13 2010-07-13 Bolder Biotechnology, Inc. Immunoglobulin fusion proteins
US20050089517A1 (en) 2003-09-23 2005-04-28 Shames Richard S. Treatment of respiratory diseases with anti-IL-2 receptor antibodies
AR091069A1 (es) * 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
AU2013289883B2 (en) * 2012-07-13 2018-11-01 Zymeworks Bc Inc. Bispecific asymmetric heterodimers comprising anti-CD3 constructs
CN105026430B (zh) * 2012-11-28 2025-03-25 酵活英属哥伦比亚有限公司 工程化免疫球蛋白重链-轻链对及其用途
EP2970486B1 (en) * 2013-03-15 2018-05-16 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
US9840545B2 (en) * 2013-09-20 2017-12-12 University Of Virginia Patent Foundation Fusion protein comprising interleukin-2 and interleukin-33
PT3102595T (pt) * 2014-02-06 2019-01-11 Hoffmann La Roche Proteínas de fusão de interleucina-2 e suas utilizações
PT3172227T (pt) 2014-07-21 2019-12-06 Delinia Inc Moléculas que ativam seletivamente células t reguladoras para o tratamento de doenças autoimuneis
AU2017378308A1 (en) 2016-12-13 2019-06-20 Delinia, Inc. Multivalent regulatory T cell modulators

Also Published As

Publication number Publication date
EP3554525A1 (en) 2019-10-23
AU2017378308A1 (en) 2019-06-20
JP2020501550A (ja) 2020-01-23
RU2019121902A3 (https=) 2021-04-21
JP7228515B2 (ja) 2023-02-24
US10472405B2 (en) 2019-11-12
WO2018112069A1 (en) 2018-06-21
BR112019011799B1 (pt) 2021-12-21
US20200031897A1 (en) 2020-01-30
CN110177564A (zh) 2019-08-27
EP3554525A4 (en) 2020-08-19
BR122020025384B1 (pt) 2022-07-12
MX381276B (es) 2025-03-12
US20180162919A1 (en) 2018-06-14
MX2021004007A (es) 2021-06-23
BR112019011799A2 (pt) 2019-10-29
MX2019007002A (es) 2019-08-22
RU2769871C2 (ru) 2022-04-07
US11059877B2 (en) 2021-07-13
RU2019121902A (ru) 2021-01-18
CA3044416A1 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
US11059877B2 (en) Multivalent regulatory T cell modulators
JP2022513406A (ja) 多価制御性ｔ細胞調節因子
JP2021519089A (ja) 二官能性タンパク質およびその作製
TW202214677A (zh) Ｉｌ－２突變體及其應用
CA3194384A1 (en) Caninized rat antibodies to canine interleukin-31 receptor alpha
JP2023506923A (ja) イヌインターロイキン－４受容体α抗体
CN117769564A (zh) 融合蛋白、药物组合物和治疗应用
KR20210005683A (ko) Cd123 및 cd3에 결합하는 이중특이적 항체의 투약
US10919976B2 (en) IFN-gamma-inducible regulatory T cell convertible anti-cancer (IRTCA) antibody and uses thereof
JP2025500805A (ja) ヒトｎｇｆに対するイヌ化およびネコ化抗体
CN119013033A (zh) 白细胞介素-2突变蛋白、融合蛋白、药物组合物以及治疗应用
WO2013103783A1 (en) Murine il-13 antibodies
CN121002060A (zh) 犬il-13的犬抗体
JP2024526080A (ja) インターロイキン１５多様体
CN116472287A (zh) 犬白介素-31受体α的犬源化抗体
JP2023548399A (ja) Ｔｇｆ－ベータファミリーの複数のリガンドを阻害する能力を有する新規の二機能性多特異性アンタゴニストおよびその使用
HK40008615A (en) Multivalent regulatory t cell modulators
JP2022527541A (ja) 抗ｈｌａ－ｃ抗体及びその使用
RU2854627C1 (ru) Биспецифические канинизированные антитела для лечения атопического дерматита
HK40052681A (en) Multivalent regulatory t cell modulators
RU2854833C1 (ru) Биспецифические канинизированные антитела и биспецифические партнеры по связыванию для лечения атопического дерматита
RU2840044C1 (ru) Антитела к собачьему альфа-рецептору интерлейкина-4
CN118725136A (zh) 抗pd-1/抗tigit双特异性抗体与il-2的融合蛋白及应用
CN118401549A (zh) 人ngf的犬源化和猫源化抗体
WO2025221933A9 (en) Antibodies and polypeptides comprising variant fc regions

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190711

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201210

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230307

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230407

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230614

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230407

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20230307

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I